Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices and accessories and services. The company is headquartered in Winter Springs, Florida and currently employs 95 full-time employees. The firm operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.
Website: iradimed.com



Growth: Good revenue growth rate 20.0%, there is slowdown compared to average historical growth rates 27.7%. The revenue growth dynamics is stable

Profitability: LTM EBITDA margin is positive, +30.9%. On average the margin is improving unsteadily. Gross margin is high, +76.1%. In the last quarter the company beat the estimated EPS, +7.1%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 1.8%. Free cash flow yield 0.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 62.0% higher than minimum and 18.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.3x by EV / Sales multiple , the company can be 42.4% overvalued

Key Financials (Download financials)

Ticker: IRMD
Share price, USD:  (-2.5%)43.59
year average price 44.59  


year start price 46.71 2023-05-09

max close price 50.61 2023-06-16

min close price 37.31 2023-10-12

current price 43.59 2024-05-07
Common stocks: 12 662 526

Dividend Yield:  1.8%
FCF Yield LTM: 0.5%
EV / LTM EBITDA: 24.2x
EV / EBITDA annualized: 25.4x
Last revenue growth (y/y):  20.0%
Last growth of EBITDA (y/y):  25.0%
Historical revenue growth:  27.7%
Historical growth of EBITDA:  81.3%
EV / Sales: 7.5x
Margin (EBITDA LTM / Revenue): 30.9%
Fundamental value created in LTM:
Market Cap ($m): 552
Net Debt ($m): -44
EV (Enterprise Value): 508
Price to Book: 7.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-04Seeking Alpha

IRADIMED CORPORATION (IRMD) Q1 2024 Earnings Call Transcript

2024-02-08Seeking Alpha

IRadimed Corporation (IRMD) Q4 2023 Earnings Call Transcript

2024-02-01GlobeNewsWire

IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.

2023-09-08Zacks Investment Research

Top 3 Profitable Stocks to Buy Now Using Net Income Ratio

2023-09-06GlobeNewsWire

IRADIMED CORPORATION to Participate at Upcoming Investor Conferences

2023-08-30Zacks Investment Research

Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why

2023-08-11Zacks Investment Research

iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why

2023-06-27Zacks Investment Research

iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable

2023-06-08Zacks Investment Research

Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why

2023-05-18Zacks Investment Research

iRadimed (IRMD) Is a Great Choice for 'Trend' Investors, Here's Why
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IRMD IRMD IRMD IRMD IRMD IRMD IRMD
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-02 2024-03-01 2023-11-03 2023-08-03 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-05-02 16:05:46 2024-03-01 08:30:34 2023-11-03 16:05:59 2023-08-03 16:07:57 2023-05-04 08:33:44 2023-03-02 17:14:13 2022-11-03 07:00:51
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 18M 17M 17M 16M 15M 15M 13M
costOfRevenue 4M 4M 4M 4M 4M 4M 3M
grossProfit 13M 13M 13M 12M 12M 11M 11M
grossProfitRatio 0.761 0.769 0.778 0.755 0.757 0.755 0.786
researchAndDevelopmentExpenses 4M 650 435 452 555 961 952 793 716 604 744 491 643
generalAndAdministrativeExpenses 4M 4M 4M 3M 4M 3M 3M
sellingAndMarketingExpenses 4M 3M 3M 3M 3M 4M 3M
sellingGeneralAndAdministrativeExpenses 5M 8M 6M 6M 7M 6M 6M
otherExpenses 0 -1M 503 192 335 387 342 409 449 733 0
operatingExpenses 9M 8M 7M 7M 8M 7M 6M
costAndExpenses 13M 12M 11M 11M 11M 11M 9M
interestIncome 0 0 0 0 0 0 0
interestExpense 0 342 409 0 0 -342 409 -448 647 -105 183
depreciationAndAmortization 226 089 3.000 189 897 187 358 182 550 -692 905 435 477
ebitda 5M 5M 6M 5M 4M 4M 5M
ebitdaratio 0.283 0.296 0.358 0.319 0.271 0.286 0.341
operatingIncome 5M 5M 6M 5M 4M 4M 4M
operatingIncomeRatio 0.270 0.296 0.358 0.308 0.259 0.286 0.308
totalOtherIncomeExpensesNet 495 151 521 813 503 192 335 387 342 409 449 733 105 183
incomeBeforeTax 5M 6M 6M 5M 4M 5M 4M
incomeBeforeTaxRatio 0.298 0.326 0.388 0.328 0.281 0.316 0.316
incomeTaxExpense 1M 1M 1M 1M 943 589 1M 810 375
netIncome 4M 5M 5M 4M 3M 4M 3M
netIncomeRatio 0.235 0.260 0.307 0.259 0.220 0.247 0.256
eps 0.330 0.360 0.400 0.330 0.270 0.290 0.270
epsdiluted 0.320 0.360 0.400 0.330 0.270 0.290 0.270
weightedAverageShsOut 13M 13M 13M 13M 13M 13M 13M
weightedAverageShsOutDil 13M 13M 13M 13M 13M 13M 13M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IRMD IRMD IRMD IRMD IRMD IRMD IRMD
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-02 2024-03-01 2023-11-03 2023-08-03 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-05-02 16:05:46 2024-03-01 08:30:34 2023-11-03 16:05:59 2023-08-03 16:07:57 2023-05-04 08:33:44 2023-03-02 17:14:13 2022-11-03 07:00:51
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 45M 50M 47M 46M 43M 58M 56M
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 45M 50M 47M 46M 43M 58M 56M
netReceivables 13M 12M 13M 11M 12M 13M 11M
inventory 13M 13M 12M 8M 6M 5M 5M
otherCurrentAssets 1M 1M 735 124 770 647 675 748 630 960 386 634
totalCurrentAssets 72M 76M 72M 66M 61M 78M 72M
propertyPlantEquipmentNet 11M 11M 9M 11M 9M 2M 5M
goodwill 0 0 0 0 0 0 0
intangibleAssets 3M 3M 2M 2M 2M 2M 2M
goodwillAndIntangibleAssets 3M 3M 2M 2M 2M 2M 2M
longTermInvestments -5M -5M -4M -4M 0 0 0
taxAssets 2M 2M 2M 2M 622 206 700 867 985 097
otherNonCurrentAssets 5M 5M 7M 4M 3M 2M 236 188
totalNonCurrentAssets 16M 16M 15M 15M 14M 7M 8M
otherAssets 1.000 1.000 0 0 0 0 0
totalAssets 88M 92M 87M 81M 76M 86M 80M
accountPayables 1M 2M 3M 3M 2M 2M 964 360
shortTermDebt 418 814 427 963 421 379 413 745 409 295 293 466 289 147
taxPayables 1M 353 282 103 223 217 496 551 979 121 919 181 877
deferredRevenue 2M 3M 2M 2M 2M 3M 2M
otherCurrentLiabilities 4M 11M 3M 3M 3M 3M 3M
totalCurrentLiabilities 8M 16M 8M 8M 7M 9M 6M
longTermDebt 2M 2M 2M 2M 2M 2M 2M
deferredRevenueNonCurrent 3M 3M 3M 3M 3M 1M 2M
deferredTaxLiabilitiesNonCurrent -3M -4M -3M -5M 0 0 0
otherNonCurrentLiabilities 3M 4M 3M 0 0 0 1M
totalNonCurrentLiabilities 4M 4M 5M 5M 5M 3M 4M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 2M 2M 2M 2M 2M 2M 2M
totalLiabilities 12M 21M 13M 12M 11M 12M 10M
preferredStock 0 0 0 0 0 0 0
commonStock 1266.000 1265.000 1260.000 1260.000 1259.000 1259.000 1256.000
retainedEarnings 47M 43M 47M 42M 37M 47M 44M
accumulatedOtherComprehensiveIncomeLoss 0 0 -0.000 0 0 0 0
othertotalStockholdersEquity 29M 28M 28M 27M 27M 26M 26M
totalStockholdersEquity 76M 71M 75M 69M 64M 74M 70M
totalEquity 76M 71M 75M 69M 64M 74M 70M
totalLiabilitiesAndStockholdersEquity 88M 92M 87M 81M 76M 86M 80M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 88M 92M 87M 81M 76M 86M 80M
totalInvestments -5M -5M -4M -4M 0 0 0
totalDebt 2M 2M 2M 2M 2M 2M 2M
netDebt -43M -48M -45M -44M -40M -56M -53M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IRMD IRMD IRMD IRMD IRMD IRMD IRMD
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-05-02 2024-03-01 2023-11-03 2023-08-03 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-05-02 16:05:46 2024-03-01 08:30:34 2023-11-03 16:05:59 2023-08-03 16:07:57 2023-05-04 08:33:44 2023-03-02 17:14:13 2022-11-03 07:00:51
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 4M 5M 5M 4M 3M 4M 3M
depreciationAndAmortization 226 089 205 378 189 897 187 358 182 550 -692 905 435 477
deferredIncomeTax 917 373 -69 042 -37 350 -1M 78 656 284 230 -82 185
stockBasedCompensation 0 551 064 533 749 568 453 533 643 426 555 393 188
changeInWorkingCapital -2M -1M -4M -352 389 177 699 -727 071 -281 168
accountsReceivables -764 322 498 857 -2M 460 884 2M -3M -2M
inventory 93 052 -1M -2M -3M -1M -405 164 -316 290
accountsPayables -640 320 -736 084 -1M 2M 105 448 1M 52 960
otherWorkingCapital -714 893 227 178 397 646 612 513 -304 904 1M 2M
otherNonCashItems 2M 33 021 27 153 74 662 267 478 74 418 46 045
netCashProvidedByOperatingActivities 4M 4M 1M 4M 5M 3M 4M
investmentsInPropertyPlantAndEquipment -478 803 -632 816 -439 023 -378 314 -7M -471 676 -556 188
acquisitionsNet 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 -8 025M 0
otherInvestingActivites -208 237 -100 913 -130 937 0 0 8 025M -363 240
netCashUsedForInvestingActivites -478 803 -632 816 -439 023 -378 314 -7M -471 676 -556 188
debtRepayment 0 -13M 0 0 0 -257 117 0
commonStockIssued 0 169 403 2.000 0 0 0 0
commonStockRepurchased 0 178 355 -31 372 0 0 0 0
dividendsPaid 0 0 0 0 -13M -13M 0
otherFinancingActivites -63 876 26M -31 371 -89 768 -49 876 13M 52 341
netCashUsedProvidedByFinancingActivities -8M -262 590 -31 370 -89 768 -13M -198 457 52 341
effectOfForexChangesOnCash 0 1M 0 -1M -1.000 1.000 0
netChangeInCash -5M 3M 922 291 3M -15M 2M 3M
cashAtEndOfPeriod 45M 50M 47M 46M 43M 58M 56M
cashAtBeginningOfPeriod 50M 47M 46M 43M 58M 56M 52M
operatingCashFlow 4M 4M 1M 4M 5M 3M 4M
capitalExpenditure -478 803 -632 816 -439 023 -378 314 -7M -471 676 -556 188
freeCashFlow 3M 3M 953 661 3M -2M 3M 3M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-08 ET (fiscal 2023 q4)
2023 q3
2023-11-03 ET (fiscal 2023 q3)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-02-02 ET (fiscal 2022 q4)
2022 q3
2022-11-05 ET (fiscal 2022 q3)
2022 q2
2022-07-29 ET (fiscal 2022 q2)
2022 q1
2022-04-29 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-05-02 12:30 ET
IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
2024-04-25 20:05 ET
IRADIMED CORPORATION to Hold 2024 First Quarter Financial Results Conference Call on May 2nd
2024-03-13 20:30 ET
IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference
2024-02-08 13:05 ET
IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results
2024-02-01 21:05 ET
IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.
2024-01-09 13:30 ET
IRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue
2024-01-02 21:30 ET
IRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-12 15:00 ET
IRADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a Special Cash Dividend of $0.48 per share
2023-11-30 14:00 ET
IRADIMED CORPORATION Named a 2024 Most Successful Small-Cap Company in America by Forbes
2023-11-03 12:00 ET
IRADIMED CORPORATION Announces Third Quarter 2023 Financial Results
2023-10-26 20:05 ET
IRADIMED CORPORATION to Hold 2023 Third Quarter Financial Results Conference Call on November 3rd
2023-09-06 20:00 ET
IRADIMED CORPORATION to Participate at Upcoming Investor Conferences
2023-08-03 12:00 ET
IRADIMED CORPORATION Announces Second Quarter 2023 Financial Results
2023-07-27 12:45 ET
IRADIMED CORPORATION to Hold 2023 Second Quarter Financial Results Conference Call on August 3rd
2023-05-10 12:30 ET
IRADIMED CORPORATION Named a 2023 Best Small Company in America by Forbes
2023-05-04 12:30 ET
IRADIMED CORPORATION Announces First Quarter 2023 Financial Results
2023-04-27 12:30 ET
IRADIMED CORPORATION to Hold 2023 First Quarter Financial Results Conference Call on May 4th
2023-03-06 13:45 ET
IRADIMED CORPORATION To Present at the 35th Annual Roth Conference
2023-02-24 21:15 ET
IRADIMED CORPORATION Issues Urgent Medical Device Correction
2023-02-02 13:00 ET
IRADIMED CORPORATION Announces Fourth Quarter and Full Year 2022 Financial Results and Announces Special Cash Dividend
2023-01-26 15:30 ET
IRADIMED CORPORATION to Hold 2022 Fourth Quarter Financial Results Conference Call on February 2nd
2023-01-18 13:00 ET
IRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022
2022-11-03 11:00 ET
IRADIMED CORPORATION Announces Third Quarter 2022 Financial Results
2022-10-27 12:00 ET
IRADIMED CORPORATION to Hold 2022 Third Quarter Financial Results Conference Call on November 3rd
2022-10-10 12:00 ET
IRADIMED CORPORATION Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA
2022-10-06 20:05 ET
IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors
2022-07-29 15:00 ET
IRADIMED CORPORATION Announces Second Quarter 2022 Financial Results
2022-07-28 17:56 ET
UPDATE - IRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th
2022-07-22 20:30 ET
IRADIMED CORPORATION to Hold 2022 Second Quarter Financial Results Conference Call on July 29th
2022-06-01 13:35 ET
Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer
2022-05-26 20:05 ET
IRADIMED Names John F. Glenn Chief Financial Officer
2022-04-29 11:00 ET
IRADIMED CORPORATION Announces First Quarter 2022 Financial Results
2022-04-28 20:00 ET
IRADIMED CORPORATION Announces Executive Transition
2022-04-05 11:00 ET
IRADIMED CORPORATION to Hold 2022 First Quarter Financial Results Conference Call on April 29th
2022-02-07 21:05 ET
IRADIMED Announces Special $1.00 Per Share Cash Dividend
2022-02-04 12:00 ET
IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results
2022-01-20 12:00 ET
IRADIMED CORPORATION to Hold 2021 Fourth Quarter Financial Results Conference Call on February 4th
2021-10-29 11:00 ET
IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results
2021-10-08 11:00 ET
IRADIMED CORPORATION to Hold 2021 Third Quarter Financial Results Conference Call on October 29th
2021-07-30 11:00 ET
IRADIMED CORPORATION Announces Second Quarter 2021 Financial Results
2021-07-07 11:00 ET
IRADIMED CORPORATION to Hold 2021 Second Quarter Financial Results Conference Call on July 30th
2021-04-30 11:00 ET
IRADIMED CORPORATION Announces First Quarter 2021 Financial Results
2021-04-09 11:00 ET
IRADIMED CORPORATION to Hold 2021 First Quarter Financial Results Conference Call on April 30th
2021-02-04 12:00 ET
IRADIMED CORPORATION Announces Fourth Quarter 2020 Financial Results
2021-01-27 12:00 ET
IRADIMED CORPORATION to Hold 2020 Fourth Quarter Financial Results Conference Call on February 4th
2020-10-30 11:00 ET
IRADIMED CORPORATION Announces Third Quarter 2020 Financial Results
2020-10-08 11:00 ET
IRADIMED CORPORATION to Hold 2020 Third Quarter Financial Results Conference Call on October 30th
2020-07-30 11:00 ET
IRADIMED CORPORATION Announces Second Quarter 2020 Financial Results
2020-07-16 11:00 ET
IRADIMED CORPORATION to Hold 2020 Second Quarter Financial Results Conference Call on July 30th
2020-05-29 11:00 ET
IRADIMED CORPORATION Names Roger Susi as President and Chief Executive Officer
2020-05-11 11:00 ET
IRADIMED CORPORATION Announces Issuance of U.S. Patent
2020-04-30 11:00 ET
IRADIMED CORPORATION Announces First Quarter 2020 Financial Results
2020-04-16 11:00 ET
IRADIMED CORPORATION to Hold 2020 First Quarter Financial Results Conference Call on April 30th
2020-04-07 11:00 ET
IRADIMED CORPORATION Withdraws 2020 Financial Guidance Due to Uncertainties from the Effects of COVID-19
2020-03-12 11:00 ET
IRADIMED CORPORATION Announces the Appointment of Lynn Neuhardt as Vice President of Research and Development
2020-03-06 14:50 ET
IRADIMED CORPORATION to Present at the 32nd Annual Roth Conference
2020-02-26 12:00 ET
IRADIMED CORPORATION Announces Retirement of Francis Casey and the Appointment of Steven Kachelmeyer as Vice President of Regulatory Affairs and Quality Assurance
2020-02-06 12:00 ET
IRADIMED CORPORATION Announces Fourth Quarter 2019 Financial Results
2020-01-22 12:00 ET
IRADIMED CORPORATION to Hold 2019 Fourth Quarter Financial Results Conference Call on February 6th
2020-01-07 12:00 ET
IRADIMED CORPORATION Announces Retirement of Brent Johnson and the Appointment of MaryBeth Smith as Vice President of Worldwide Sales
2019-12-12 13:55 ET
IRADIMED CORPORATION Completes CE Mark Renewal Process For Its MRI Compatible Patient Vital Signs Monitoring System
2019-10-30 11:00 ET
IRADIMED CORPORATION Announces Third Quarter 2019 Financial Results
2019-10-16 11:00 ET
IRADIMED CORPORATION to Hold 2019 Third Quarter Financial Results Conference Call on October 30th
2019-10-08 11:00 ET
IRADIMED CORPORATION Resolves Warning Letter Related to Its Infusion Pump System

SEC forms

Show financial reports only

SEC form 10
2024-05-02 16:05 ET
IRadimed Corporation published news for 2024 q1
SEC form 8
2024-05-02 08:30 ET
IRadimed Corporation published news for 2024 q1
SEC form 8
2024-05-02 08:30 ET
IRadimed Corporation reported for 2024 q1
SEC form 10
2024-05-02 00:00 ET
IRadimed Corporation published news for 2024 q1
SEC form 10
2024-03-01 00:00 ET
IRadimed Corporation published news for 2023 q4
SEC form 8
2024-02-08 00:00 ET
IRadimed Corporation published news for 2023 q4
SEC form 8
2024-02-08 00:00 ET
IRadimed Corporation reported for 2023 q4
SEC form 10
2023-11-03 16:05 ET
IRadimed Corporation published news for 2023 q3
SEC form 8
2023-11-03 08:00 ET
IRadimed Corporation reported for 2023 q3
SEC form 10
2023-11-03 00:00 ET
IRadimed Corporation published news for 2023 q3
SEC form 10
2023-08-03 16:07 ET
IRadimed Corporation published news for 2023 q2
SEC form 6
2023-08-03 08:00 ET
IRadimed Corporation reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
IRadimed Corporation published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
IRadimed Corporation published news for 2023 q2
SEC form 6
2023-06-15 16:30 ET
IRadimed Corporation published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
IRadimed Corporation published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
IRadimed Corporation published news for 2023 q1
SEC form 6
2023-04-28 16:15 ET
IRadimed Corporation published news for 2023 q1
SEC form 10
2023-03-02 17:14 ET
IRadimed Corporation reported for 2022 q4
SEC form 10
2023-03-02 00:00 ET
IRadimed Corporation published news for 2022 q4
SEC form 6
2023-02-07 16:02 ET
IRadimed Corporation published news for 2022 q4
SEC form 6
2023-02-03 16:02 ET
IRadimed Corporation published news for 2022 q4
SEC form 6
2023-02-02 17:17 ET
IRadimed Corporation published news for 2022 q4
SEC form 8
2023-02-02 00:00 ET
IRadimed Corporation published news for 2022 q4
SEC form 8
2023-01-19 00:00 ET
IRadimed Corporation published news for 2022 q4
SEC form 6
2023-01-18 19:23 ET
IRadimed Corporation published news for 2022 q4
SEC form 6
2022-11-04 16:06 ET
IRadimed Corporation published news for 2022 q3
SEC form 6
2022-11-03 07:00 ET
IRadimed Corporation published news for 2022 q3
SEC form 10
2022-11-03 07:00 ET
IRadimed Corporation reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
IRadimed Corporation reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
IRadimed Corporation reported for 2022 q3
SEC form 6
2022-10-11 16:07 ET
IRadimed Corporation published news for 2022 q3
SEC form 8
2022-10-11 00:00 ET
IRadimed Corporation published news for 2022 q3
SEC form 6
2022-10-06 16:08 ET
IRadimed Corporation published news for 2022 q3
SEC form 10
2022-08-05 07:00 ET
IRadimed Corporation reported for 2022 q2
SEC form 10
2022-08-05 00:00 ET
IRadimed Corporation reported for 2022 q2
SEC form 6
2022-07-29 08:29 ET
IRadimed Corporation published news for 2022 q2
SEC form 8
2022-07-29 00:00 ET
IRadimed Corporation reported for 2022 q2
SEC form 6
2022-06-13 16:24 ET
IRadimed Corporation published news for 2022 q1
SEC form 6
2022-05-26 16:07 ET
IRadimed Corporation published news for 2022 q1
SEC form 10
2022-05-06 07:00 ET
IRadimed Corporation reported for 2022 q1
SEC form 10
2022-05-06 00:00 ET
IRadimed Corporation reported for 2022 q1
SEC form 6
2022-04-29 07:00 ET
IRadimed Corporation published news for 2022 q1
SEC form 8
2022-04-29 00:00 ET
IRadimed Corporation reported for 2022 q1
SEC form 6
2022-04-28 19:44 ET
IRadimed Corporation published news for 2022 q1
SEC form 6
2022-04-27 07:00 ET
IRadimed Corporation published news for 2022 q1
SEC form 10
2022-03-04 07:00 ET
IRadimed Corporation published news for 2021 q4
SEC form 10
2022-03-04 00:00 ET
IRadimed Corporation published news for 2021 q4
SEC form 6
2022-02-07 16:00 ET
IRadimed Corporation published news for 2021 q4
SEC form 6
2022-02-04 07:00 ET
IRadimed Corporation published news for 2021 q4
SEC form 8
2022-02-04 00:00 ET
IRadimed Corporation published news for 2021 q4
SEC form 6
2021-11-23 16:39 ET
IRadimed Corporation published news for 2021 q3
SEC form 10
2021-11-05 07:00 ET
IRadimed Corporation published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
IRadimed Corporation published news for 2021 q3
SEC form 6
2021-10-29 07:00 ET
IRadimed Corporation published news for 2021 q3
SEC form 8
2021-10-29 00:00 ET
IRadimed Corporation published news for 2021 q3
SEC form 10
2021-08-06 07:00 ET
IRadimed Corporation published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
IRadimed Corporation published news for 2021 q2
SEC form 6
2021-07-30 07:00 ET
IRadimed Corporation published news for 2021 q2
SEC form 8
2021-07-30 00:00 ET
IRadimed Corporation published news for 2021 q2
SEC form 6
2021-07-12 17:22 ET
IRadimed Corporation published news for 2021 q2
SEC form 6
2021-06-17 17:25 ET
IRadimed Corporation published news for 2021 q1
SEC form 6
2021-06-14 16:02 ET
IRadimed Corporation published news for 2021 q1
SEC form 10
2021-05-07 07:07 ET
IRadimed Corporation published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
IRadimed Corporation published news for 2021 q1
SEC form 6
2021-04-30 07:02 ET
IRadimed Corporation published news for 2021 q1
SEC form 8
2021-04-30 00:00 ET
IRadimed Corporation published news for 2021 q1
SEC form 6
2021-04-28 16:15 ET
IRadimed Corporation published news for 2021 q1
SEC form 10
2021-03-05 07:01 ET
IRadimed Corporation published news for 2020 q4
SEC form 6
2021-02-11 07:01 ET
IRadimed Corporation published news for 2020 q4
SEC form 6
2021-02-04 07:00 ET
IRadimed Corporation published news for 2020 q4
SEC form 10
2020-11-06 07:00 ET
IRadimed Corporation published news for 2020 q3
SEC form 6
2020-10-30 07:01 ET
IRadimed Corporation published news for 2020 q3